Fibrinolysin

Fibrinolysin has anticoagulant effects on human blood.

The drug prevents blood coagulation. It has the ability to break down fibrin protein threads - has an effect similar to the action of the proteolytic enzyme. The most effective fibrinolysin is in the case of its application at the initial stage - immediately in the event of the occurrence of fibrin clots and thrombus formation. Further therapeutic efficacy is impaired in accordance with the duration of the presence of a thrombus.

[1], [2], [3], [4], [5], [6], [7], [8],

Indications Fibrinolysin

The tool in bottles is used for such disorders:

• thromboembolism affecting the pulmonary or peripheral arteries;
• thrombophlebitis in the active phase;
• affecting the cerebral vessels thromboembolism;
• exacerbated thrombophlebitis, which is chronic;
• myocardial infarction.

The use of drugs in ampoules:

• hemorrhages in the area of the optic organs, having a traumatic origin (at least 4 days after receiving intraocular damage);
• hemorrhages affecting the vitreous body, and at the same time the retina or the anterior region of the eye chamber;
• affecting the central vessels located inside the eye (arteries or veins), together with their branches, thrombosis.

[9]

Release form

The release of the element is realized in the form of an injection lyophilisate - inside the flasks with a capacity of 20,000 IU (1 piece) or ampoules with a volume of 300 IU (10 pieces).

[10], [11], [12]

Pharmacodynamics

Fibrinolysin is a human plasma element produced by trypsin, which activates the intraplasma profibrinolysin through enzymes.

The therapeutic effect of fibrinolysin is determined by a biological method of determining how it performs the lysis of a normal fresh fibrin clot under conditions of a temperature of 37 ° C for half an hour, and is indicated in ED.

[13], [14], [15], [16], [17]

Dosing and administration

Use of medication from flakonchikov.

In the case of myocardial infarction or cerebral thrombosis, it is necessary to administer the medication during the initial 6 hours. Thrombosis, which affects the peripheral arteries, requires infusion in the initial 12 hours. During thrombosis associated with peripheral veins, it is necessary to make an injection in the period of 5-7 days from the moment of detection of thrombosis.

The drug is used in the form of infusions. Before the infusion procedure, the powder from the vial is dissolved in 9% NaCl in the proportion of 100-160 U / ml. Then, heparin is added to the resulting solution in a ratio of 10,000 units of heparin to fibrinolysin, 20,000 units. First, infusion is performed at a speed of 10-12 drops / minute. You can also increase the speed to 15-20 drops / minute (if good tolerability is observed). The total size of servings per day varies in the range of 20000-40000 IU, with a procedure duration of at least 3 hours. It should be borne in mind that Fibrinolizin does not contain a stabilizer, and therefore the finished liquid quickly loses its drug activity.

Upon completion of the infusion of the drug, together with heparin, intramuscular or intravenous administration of only heparin in a portion of 40000-60000 IU / day within 2-3 days should be carried out. In this case, its dose is gradually reduced, and then there is a transition to the introduction of indirect anticoagulants.

The introduction of the drug in ampoules.

A portion of the drug, constituting 300 U, is used only in the subconjunctival way. Before performing the procedure, the substance from the 1st ampoule is dissolved in the injection liquid (0.5 ml). The finished substance is injected under the conjunctiva in the sclera or the transitional fold located below (before this, you also need to perform the introduction of 0.5% dikaina in the conjunctival sac - as anesthesia).

Repeated injections should be performed after 1-2 days. The total number of injections varies in the range of 3-10, taking into account the existing indications.

[30], [31], [32], [33], [34], [35]

Use Fibrinolysin during pregnancy

It is forbidden to enter the drug during pregnancy or HB.

[18], [19],

Contraindications

Among the contraindications in vials:

• hemorrhagic diathesis;
• acute phase of hepatitis;
• open wounds;
• fibrinogenopenia;
• increased sensitivity;
• bleeding;
• hepatic cirrhosis;
• radiation sickness;
• ulcer affecting the gastrointestinal tract;
• nephritis;
• pulmonary tuberculosis in the active phase;
• history of anaphylactic manifestations;
• recently transferred (within 10 days) biopsy, operation, puncture in the area of large vessels or injury;
• very high blood pressure accompanying brain damage.

Contraindications for drugs in ampoules:

• severe intolerance to the drug;
• history of anaphylactic symptoms;
• contraindications regarding dicain, because it is administered before using Fibrinolysin.

[20], [21], [22], [23], [24]

Side effects Fibrinolysin

Among the adverse signs of medication in bottles:

• allergy symptoms (feverish among them, facial hyperemia and urticaria);
• decrease in blood pressure (monitor the pressure when using drugs);
• pains affecting the abdominal area or sternum;
• bleeding;
• pain or other changes in the area of the injection.

When using ampoules:

• signs of allergy (urticaria, facial hyperemia or local edema);
• pain or changes in the injection area.

In the event of such violations, you need to reduce the speed of the injection, and with the development of pronounced manifestations, the injection is stopped. To eliminate the negative symptoms, use antihistamine or cardiovascular drugs and promedol (chosen taking into account the orientation of the disorders).

[25], [26], [27], [28], [29],

Overdose

After intravenous administration of large portions, bleeding may occur.

With such a violation, you need to stop the infusion and perform intravenous infusion of aminocaproic acid and plasma.

[36], [37], [38], [39], [40]

Storage conditions

Fibrinolysin is required to be maintained at temperature indications in the range of elevations 2-8 ° C.

[41], [42], [43]

Shelf life

Fibrinolysin can be used within a 24-month term from the time the drug was manufactured.

[44], [45],

Application for children

The drug is not prescribed to children.

[46], [47], [48], [49], [50], [51], [52], [53], [54]

Analogs

Analogues of drugs are medicines Zigris, Distreptaz, Metalise with Celiasis, and besides this Aktilize, Tobarpin, Streptokinase with Elaksim, Trombovazim and Hemaza. Also on the list is Eberkinase and Biostrapta.

[55], [56], [57], [58], [59]

Reviews

Fibrinolysin receives very little feedback from patients. Most likely this is due to the specific use of the drug. Use the substance should be under the supervision of a medical professional, because it has a fairly extensive number of negative signs and contraindications.

[60], [61], [62], [63], [64]